scispace - formally typeset
Search or ask a question
Author

Jonathan Beesley

Bio: Jonathan Beesley is an academic researcher from QIMR Berghofer Medical Research Institute. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 56, co-authored 158 publications receiving 14106 citations. Previous affiliations of Jonathan Beesley include Peter MacCallum Cancer Centre & Royal Brisbane and Women's Hospital.


Papers
More filters
Journal ArticleDOI
Douglas F. Easton1, Karen A. Pooley1, Alison M. Dunning1, Paul D.P. Pharoah1, Deborah J. Thompson1, Dennis G. Ballinger, Jeffery P. Struewing2, Jonathan J. Morrison1, Helen I. Field1, Robert Luben1, Nicholas J. Wareham1, Shahana Ahmed1, Catherine S. Healey1, Richard Bowman, Kerstin B. Meyer1, Christopher A. Haiman3, Laurence K. Kolonel, Brian E. Henderson3, Loic Le Marchand, Paul Brennan4, Suleeporn Sangrajrang, Valerie Gaborieau4, Fabrice Odefrey4, Chen-Yang Shen5, Pei-Ei Wu5, Hui-Chun Wang5, Diana Eccles6, D. Gareth Evans7, Julian Peto8, Olivia Fletcher9, Nichola Johnson9, Sheila Seal, Michael R. Stratton10, Nazneen Rahman, Georgia Chenevix-Trench11, Georgia Chenevix-Trench12, Stig E. Bojesen13, Børge G. Nordestgaard13, C K Axelsson13, Montserrat Garcia-Closas2, Louise A. Brinton2, Stephen J. Chanock2, Jolanta Lissowska14, Beata Peplonska15, Heli Nevanlinna16, Rainer Fagerholm16, H Eerola16, Daehee Kang17, Keun-Young Yoo17, Dong-Young Noh17, Sei Hyun Ahn18, David J. Hunter19, Susan E. Hankinson19, David G. Cox19, Per Hall20, Sara Wedrén20, Jianjun Liu21, Yen-Ling Low21, Natalia Bogdanova22, Peter Schu¨rmann22, Do¨rk Do¨rk22, Rob A. E. M. Tollenaar23, Catharina E. Jacobi23, Peter Devilee23, Jan G. M. Klijn24, Alice J. Sigurdson2, Michele M. Doody2, Bruce H. Alexander25, Jinghui Zhang2, Angela Cox26, Ian W. Brock26, Gordon MacPherson26, Malcolm W.R. Reed26, Fergus J. Couch27, Ellen L. Goode27, Janet E. Olson27, Hanne Meijers-Heijboer24, Hanne Meijers-Heijboer28, Ans M.W. van den Ouweland24, André G. Uitterlinden24, Fernando Rivadeneira24, Roger L. Milne29, Gloria Ribas29, Anna González-Neira29, Javier Benitez29, John L. Hopper30, Margaret R. E. McCredie31, Margaret R. E. McCredie32, Margaret R. E. McCredie12, Melissa C. Southey12, Melissa C. Southey30, Graham G. Giles33, Chris Schroen30, Christina Justenhoven34, Christina Justenhoven35, Hiltrud Brauch34, Hiltrud Brauch35, Ute Hamann36, Yon-Dschun Ko, Amanda B. Spurdle11, Jonathan Beesley11, Xiaoqing Chen11, _ kConFab37, Arto Mannermaa37, Veli-Matti Kosma37, Vesa Kataja37, Jaana M. Hartikainen37, Nicholas E. Day1, David Cox, Bruce A.J. Ponder1 
28 Jun 2007-Nature
TL;DR: To identify further susceptibility alleles, a two-stage genome-wide association study in 4,398 breast cancer cases and 4,316 controls was conducted, followed by a third stage in which 30 single nucleotide polymorphisms were tested for confirmation.
Abstract: Breast cancer exhibits familial aggregation, consistent with variation in genetic susceptibility to the disease. Known susceptibility genes account for less than 25% of the familial risk of breast cancer, and the residual genetic variance is likely to be due to variants conferring more moderate risks. To identify further susceptibility alleles, we conducted a two-stage genome-wide association study in 4,398 breast cancer cases and 4,316 controls, followed by a third stage in which 30 single nucleotide polymorphisms (SNPs) were tested for confirmation in 21,860 cases and 22,578 controls from 22 studies. We used 227,876 SNPs that were estimated to correlate with 77% of known common SNPs in Europeans at r2.0.5. SNPs in five novel independent loci exhibited strong and consistent evidence of association with breast cancer (P,1027). Four of these contain plausible causative genes (FGFR2, TNRC9, MAP3K1 and LSP1). At the second stage, 1,792 SNPs were significant at the P,0.05 level compared with an estimated 1,343 that would be expected by chance, indicating that many additional common susceptibility alleles may be identifiable by this approach.

2,288 citations

Journal ArticleDOI
02 Nov 2017-Nature
TL;DR: A genome-wide association study of breast cancer in 122,977 cases and 105,974 controls of European ancestry and 14,068 cases and 13,104 controls of East Asian ancestry finds that heritability of Breast cancer due to all single-nucleotide polymorphisms in regulatory features was 2–5-fold enriched relative to the genome- wide average.
Abstract: Breast cancer risk is influenced by rare coding variants in susceptibility genes, such as BRCA1, and many common, mostly non-coding variants. However, much of the genetic contribution to breast cancer risk remains unknown. Here we report the results of a genome-wide association study of breast cancer in 122,977 cases and 105,974 controls of European ancestry and 14,068 cases and 13,104 controls of East Asian ancestry. We identified 65 new loci that are associated with overall breast cancer risk at P < 5 × 10-8. The majority of credible risk single-nucleotide polymorphisms in these loci fall in distal regulatory elements, and by integrating in silico data to predict target genes in breast cells at each locus, we demonstrate a strong overlap between candidate target genes and somatic driver genes in breast tumours. We also find that heritability of breast cancer due to all single-nucleotide polymorphisms in regulatory features was 2-5-fold enriched relative to the genome-wide average, with strong enrichment for particular transcription factor binding sites. These results provide further insight into genetic susceptibility to breast cancer and will improve the use of genetic risk scores for individualized screening and prevention.

1,014 citations

Journal ArticleDOI
TL;DR: Recent approaches to the functional follow-up of GWAS loci, including fine mapping ofGWAS signal(s), prioritization of putative functional SNPs by the integration of genetic epidemiological and bioinformatic methods, and in vitro and in-vivo experimental verification of predicted molecular mechanisms for identifying the targeted genes are reviewed.
Abstract: Genome-wide association studies (GWASs) have enabled the discovery of common genetic variation contributing to normal and pathological traits and clinical drug responses, but recognizing the precise targets of these associations is now the major challenge. Here, we review recent approaches to the functional follow-up of GWAS loci, including fine mapping of GWAS signal(s), prioritization of putative functional SNPs by the integration of genetic epidemiological and bioinformatic methods, and in vitro and in vivo experimental verification of predicted molecular mechanisms for identifying the targeted genes. The majority of GWAS-identified variants fall in noncoding regions of the genome. Therefore, this review focuses on strategies for assessing likely mechanisms affected by noncoding variants; such mechanisms include transcriptional regulation, noncoding RNA function, and epigenetic regulation. These approaches have already accelerated progress from genetic studies to biological knowledge and might ultimately guide the development of prognostic, preventive, and therapeutic measures.

714 citations

Journal ArticleDOI
Angela Cox1, Alison M. Dunning2, Montserrat Garcia-Closas3, Sabapathy P. Balasubramanian1, Malcolm W.R. Reed1, Karen A. Pooley2, Serena Scollen2, Caroline Baynes2, Bruce A.J. Ponder2, Stephen J. Chanock3, Jolanta Lissowska4, Louise A. Brinton3, Beata Peplonska5, Melissa C. Southey6, John L. Hopper6, Margaret R. E. McCredie7, Graham G. Giles8, Olivia Fletcher9, Nichola Johnson9, Isabel dos Santos Silva9, Lorna Gibson9, Stig E. Bojesen10, Børge G. Nordestgaard10, C K Axelsson10, Diana Torres11, Ute Hamann11, Christina Justenhoven12, Christina Justenhoven13, Hiltrud Brauch12, Hiltrud Brauch13, Jenny Chang-Claude11, Silke Kropp11, Angela Risch11, Shan Wang-Gohrke14, Peter Schürmann15, Natalia Bogdanova15, Thilo Dörk15, Rainer Fagerholm16, Kirsimari Aaltonen16, Carl Blomqvist16, Heli Nevanlinna16, Sheila Seal, Anthony Renwick, Michael R. Stratton, Nazneen Rahman, Suleeporn Sangrajrang, David J. Hughes17, Fabrice Odefrey17, Paul Brennan17, Amanda B. Spurdle18, Georgia Chenevix-Trench18, Jonathan Beesley18, Arto Mannermaa19, Jaana M. Hartikainen19, Vesa Kataja19, Veli-Matti Kosma19, Fergus J. Couch20, Janet E. Olson20, Ellen L. Goode20, Annegien Broeks21, Marjanka K. Schmidt21, Frans B. L. Hogervorst21, Laura J. van't Veer21, Daehee Kang22, Keun-Young Yoo22, Dong Young Noh22, Sei Hyun Ahn23, Sara Wedrén24, Per Hall24, Yen-Ling Low25, Jianjun Liu25, Roger L. Milne26, Gloria Ribas26, Anna González-Neira26, Javier Benitez26, Alice J. Sigurdson3, Alice J. Sigurdson27, Denise L. Stredrick27, Denise L. Stredrick3, Bruce H. Alexander3, Bruce H. Alexander27, Jeffery P. Struewing3, Jeffery P. Struewing27, Paul D.P. Pharoah2, Douglas F. Easton2 
TL;DR: It is demonstrated that common breast cancer susceptibility alleles with small effects on risk can be identified, given sufficiently powerful studies, as well as the need for further studies to confirm putative genetic associations with breast cancer.
Abstract: The Breast Cancer Association Consortium (BCAC) has been established to conduct combined case-control analyses with augmented statistical power to try to confirm putative genetic associations with breast cancer. We genotyped nine SNPs for which there was some prior evidence of an association with breast cancer: CASP8 D302H (rs1045485), IGFBP3 -202 C --> A (rs2854744), SOD2 V16A (rs1799725), TGFB1 L10P (rs1982073), ATM S49C (rs1800054), ADH1B 3' UTR A --> G (rs1042026), CDKN1A S31R (rs1801270), ICAM5 V301I (rs1056538) and NUMA1 A794G (rs3750913). We included data from 9-15 studies, comprising 11,391-18,290 cases and 14,753-22,670 controls. We found evidence of an association with breast cancer for CASP8 D302H (with odds ratios (OR) of 0.89 (95% confidence interval (c.i.): 0.85-0.94) and 0.74 (95% c.i.: 0.62-0.87) for heterozygotes and rare homozygotes, respectively, compared with common homozygotes; P(trend) = 1.1 x 10(-7)) and weaker evidence for TGFB1 L10P (OR = 1.07 (95% c.i.: 1.02-1.13) and 1.16 (95% c.i.: 1.08-1.25), respectively; P(trend) = 2.8 x 10(-5)). These results demonstrate that common breast cancer susceptibility alleles with small effects on risk can be identified, given sufficiently powerful studies.

567 citations

Journal ArticleDOI
TL;DR: 15 new loci associated with breast cancer at P < 5 × 10−8 are identified, and one association appears to be driven by an amino acid substitution encoded in EXO1, which is found in women of European ancestry.
Abstract: Genome-wide association studies (GWAS) and large-scale replication studies have identified common variants in 79 loci associated with breast cancer, explaining ∼14% of the familial risk of the disease. To identify new susceptibility loci, we performed a meta-analysis of 11 GWAS, comprising 15,748 breast cancer cases and 18,084 controls together with 46,785 cases and 42,892 controls from 41 studies genotyped on a 211,155-marker custom array (iCOGS). Analyses were restricted to women of European ancestry. We generated genotypes for more than 11 million SNPs by imputation using the 1000 Genomes Project reference panel, and we identified 15 new loci associated with breast cancer at P < 5 × 10(-8). Combining association analysis with ChIP-seq chromatin binding data in mammary cell lines and ChIA-PET chromatin interaction data from ENCODE, we identified likely target genes in two regions: SETBP1 at 18q12.3 and RNF115 and PDZK1 at 1q21.1. One association appears to be driven by an amino acid substitution encoded in EXO1.

523 citations


Cited by
More filters
Journal ArticleDOI
08 Oct 2009-Nature
TL;DR: This paper examined potential sources of missing heritability and proposed research strategies, including and extending beyond current genome-wide association approaches, to illuminate the genetics of complex diseases and enhance its potential to enable effective disease prevention or treatment.
Abstract: Genome-wide association studies have identified hundreds of genetic variants associated with complex human diseases and traits, and have provided valuable insights into their genetic architecture. Most variants identified so far confer relatively small increments in risk, and explain only a small proportion of familial clustering, leading many to question how the remaining, 'missing' heritability can be explained. Here we examine potential sources of missing heritability and propose research strategies, including and extending beyond current genome-wide association approaches, to illuminate the genetics of complex diseases and enhance its potential to enable effective disease prevention or treatment.

7,797 citations

01 Feb 2015
TL;DR: In this article, the authors describe the integrative analysis of 111 reference human epigenomes generated as part of the NIH Roadmap Epigenomics Consortium, profiled for histone modification patterns, DNA accessibility, DNA methylation and RNA expression.
Abstract: The reference human genome sequence set the stage for studies of genetic variation and its association with human disease, but epigenomic studies lack a similar reference. To address this need, the NIH Roadmap Epigenomics Consortium generated the largest collection so far of human epigenomes for primary cells and tissues. Here we describe the integrative analysis of 111 reference human epigenomes generated as part of the programme, profiled for histone modification patterns, DNA accessibility, DNA methylation and RNA expression. We establish global maps of regulatory elements, define regulatory modules of coordinated activity, and their likely activators and repressors. We show that disease- and trait-associated genetic variants are enriched in tissue-specific epigenomic marks, revealing biologically relevant cell types for diverse human traits, and providing a resource for interpreting the molecular basis of human disease. Our results demonstrate the central role of epigenomic information for understanding gene regulation, cellular differentiation and human disease.

4,409 citations

Journal ArticleDOI
TL;DR: It is proposed that DNA methylation age measures the cumulative effect of an epigenetic maintenance system, and can be used to address a host of questions in developmental biology, cancer and aging research.
Abstract: It is not yet known whether DNA methylation levels can be used to accurately predict age across a broad spectrum of human tissues and cell types, nor whether the resulting age prediction is a biologically meaningful measure. I developed a multi-tissue predictor of age that allows one to estimate the DNA methylation age of most tissues and cell types. The predictor, which is freely available, was developed using 8,000 samples from 82 Illumina DNA methylation array datasets, encompassing 51 healthy tissues and cell types. I found that DNA methylation age has the following properties: first, it is close to zero for embryonic and induced pluripotent stem cells; second, it correlates with cell passage number; third, it gives rise to a highly heritable measure of age acceleration; and, fourth, it is applicable to chimpanzee tissues. Analysis of 6,000 cancer samples from 32 datasets showed that all of the considered 20 cancer types exhibit significant age acceleration, with an average of 36 years. Low age-acceleration of cancer tissue is associated with a high number of somatic mutations and TP53 mutations, while mutations in steroid receptors greatly accelerate DNA methylation age in breast cancer. Finally, I characterize the 353 CpG sites that together form an aging clock in terms of chromatin states and tissue variance. I propose that DNA methylation age measures the cumulative effect of an epigenetic maintenance system. This novel epigenetic clock can be used to address a host of questions in developmental biology, cancer and aging research.

4,233 citations

Journal ArticleDOI
TL;DR: This Review highlights the knowledge gained, defines areas of emerging consensus, and describes the challenges that remain as researchers seek to obtain more complete descriptions of the susceptibility architecture of biomedical traits of interest and to translate the information gathered into improvements in clinical management.
Abstract: The past year has witnessed substantial advances in understanding the genetic basis of many common phenotypes of biomedical importance. These advances have been the result of systematic, well-powered, genome-wide surveys exploring the relationships between common sequence variation and disease predisposition. This approach has revealed over 50 disease-susceptibility loci and has provided insights into the allelic architecture of multifactorial traits. At the same time, much has been learned about the successful prosecution of association studies on such a scale. This Review highlights the knowledge gained, defines areas of emerging consensus, and describes the challenges that remain as researchers seek to obtain more complete descriptions of the susceptibility architecture of biomedical traits of interest and to translate the information gathered into improvements in clinical management.

2,908 citations

Journal ArticleDOI
TL;DR: Improved data access is improved with the release of a new RESTful API to support high-throughput programmatic access, an improved web interface and a new summary statistics database.
Abstract: The GWAS Catalog delivers a high-quality curated collection of all published genome-wide association studies enabling investigations to identify causal variants, understand disease mechanisms, and establish targets for novel therapies. The scope of the Catalog has also expanded to targeted and exome arrays with 1000 new associations added for these technologies. As of September 2018, the Catalog contains 5687 GWAS comprising 71673 variant-trait associations from 3567 publications. New content includes 284 full P-value summary statistics datasets for genome-wide and new targeted array studies, representing 6 × 109 individual variant-trait statistics. In the last 12 months, the Catalog's user interface was accessed by ∼90000 unique users who viewed >1 million pages. We have improved data access with the release of a new RESTful API to support high-throughput programmatic access, an improved web interface and a new summary statistics database. Summary statistics provision is supported by a new format proposed as a community standard for summary statistics data representation. This format was derived from our experience in standardizing heterogeneous submissions, mapping formats and in harmonizing content. Availability: https://www.ebi.ac.uk/gwas/.

2,878 citations